A glimpse to the future: The ARV pipeline up to 2030 - how do we ensure it is affordable and acceptable? Helen McDowell Head of Government Affairs & Global Public Health 24 July 2018 AIDS 2018

Conflicts of interest I am a full time permanent employee of ViiV Healthcare and hold shares in GlaxoSmithKline (majority shareholder of ViiV Healthcare)

Community insights drive our efforts We listen and engage with people living with HIV and use these insights to inform and drive everything we do

No one should take more medicine than they need Reducing long term effect of HIV medication on the body ranked as the most important improvement among PLHIV 72% PLHIV worry about long-term effects of HIV treatments 56% PLHIV would consider reducing the number of drugs in their regimen to the minimum Positive Perspectives Survey, presented at EACS 2017

Investing in innovative R&D to benefit PLHIV Our focus areas have the potential to change the way we treat HIV with the goal to reduce long-term toxicities Small molecule ARVs Biologic (monoclonal antibody) ARVs Alternative methods of delivery (e.g. long-acting injectables) Simplified regimens with improved long-term outcomes Maturation inhibitor as possible addition to arsenal of treatment options Attachment inhibitor for heavily treatment-experienced patients Ensure what we do helps PLHIV Involve PLHIV in process PLHIV benefit from our R&D efforts

Our pipeline makes a difference to PLHIV Pipeline strategy Long-acting Treatment Regimens cabotegravir + rilpivirine* Prevention cabotegravir long-acting* Search for Remission and Cure Legacy ARV Drug Portfolio abacavir/lamivudine, maraviroc & others Dolutegravir-based Regimens Tivicay Triumeq Two Drug Regimens dolutegravir/rilpivirine* dolutegravir/lamivudine* New MOA attachment inhibitor (fostemsavir)* Combinectin (GSK3732394)*ǂ maturation inhibitor portfolio*ǂ allosteric integrase inhibitor *ǂ capsid inhibitor*ǂ New treatment paradigm = 2DR Current standard of care = HAART/legacy drugs *investigational treatments ǂDiscovery program

Enabling global access and uptake: Collaboration is key Research and Development and Product Registration Patents and Voluntary Licensing Flexible Pricing and Local Manufacturing Healthcare and Community Capacity Building